{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:41:00Z","timestamp":1792449660624,"version":"4.5.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16GW0360"],"award-info":[{"award-number":["16GW0360"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004937","name":"Bundesministerium f\u00fcr Forschung und Technologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["MA 2183\/3-1"],"award-info":[{"award-number":["MA 2183\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejmech.2025.117849","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T10:08:21Z","timestamp":1749377301000},"page":"117849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Novel water-soluble and highly efficient dual type I\/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3)"],"prefix":"10.1016","volume":"296","author":[{"given":"Andreas","family":"Sellmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Able","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Reinecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Utpatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Pongratz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Plank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Elz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrei","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belay","family":"Tizazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Herbert","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-6538","authenticated-orcid":false,"given":"Siavosh","family":"Mahboobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117849_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117849_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.0013-0427.2003.00027.x","article-title":"Burnett alan. Review article","volume":"70","author":"Bob","year":"2003","journal-title":"Economica"},{"key":"10.1016\/j.ejmech.2025.117849_bib3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117849_bib5","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2025.117849_bib6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib7","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ejmech.2025.117849_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117849_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0092-8674(95)90404-2","article-title":"Dimerization of cell surface receptors in signal transduction","volume":"80","author":"Heldin","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117849_bib10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/1042819031000067503","article-title":"Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia","volume":"44","author":"Kottaridis","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2025.117849_bib11","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1634\/stemcells.2005-0519","article-title":"FMS-Like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia","volume":"24","author":"Parcells","year":"2006","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2025.117849_bib13","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib14","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1158\/0008-5472.CAN-05-0422","article-title":"Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation","volume":"65","author":"Brandts","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117849_bib15","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib17","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.02850.x","article-title":"Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia","volume":"113","author":"Abu-Duhier","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2025.117849_bib18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib19","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood-2005-06-2596","article-title":"Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML","volume":"107","author":"Reindl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10428194.2013.800198","article-title":"FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations","volume":"55","author":"Kayser","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejmech.2025.117849_bib21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.117849_bib22","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOH.0b013e3283439a03","article-title":"FLT3 inhibitors: a story of the old and the new","volume":"18","author":"Fathi","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ejmech.2025.117849_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-013-1334-8","article-title":"FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance","volume":"97","author":"Grunwald","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ejmech.2025.117849_bib25","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","article-title":"Drug therapy for acute myeloid leukemia","volume":"106","author":"Tallman","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in Acute Myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117849_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in Acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.117849_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib30","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib31","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117849_bib32","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib33","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","article-title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","volume":"108","author":"Knapper","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(02)00070-3","article-title":"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)","volume":"1","author":"Kelly","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117849_bib35","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.V104.11.1792.1792","article-title":"Phase II evaluation of the tyrosine kinase inhibitor MLN518 in patients with acute Myeloid Leukemia (AML) bearing a FLT3 Internal Tandem Duplication (ITD) mutation","volume":"104","author":"Angelo","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib36","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.4161\/cc.8.16.9355","article-title":"The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin","volume":"8","author":"Schittenhelm","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2025.117849_bib37","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2002-10-3023","article-title":"SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes","volume":"102","author":"Giles","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.leukres.2003.11.004","article-title":"Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia","volume":"28","author":"O'Farrell","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.117849_bib39","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","article-title":"A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia","volume":"102","author":"Fiedler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib41","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib42","first-page":"5465","article-title":"An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients","volume":"9","author":"O'Farrell","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117849_bib43","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood.V114.22.2060.2060","article-title":"Compassionate use of sorafenib in relapsed and refractory Flt3-ITD positive acute Myeloid leukemia","volume":"114","author":"Metzelder","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib44","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood.V114.22.636.636","article-title":"AC220, a potent, selective, second generation FLT3 Receptor Tyrosine Kinase (RTK) inhibitor, in a first-in-human (FIH) phase 1 AML study","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib46","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib47","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.117849_bib48","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.ejmech.2025.117849_bib49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib50","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117849_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112232","article-title":"A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia","volume":"193","author":"Sellmer","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/leu.2012.195","article-title":"FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia","volume":"27","author":"Leung","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib53","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1021\/acs.jmedchem.0c01851","article-title":"FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib54","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/13543780903179278","article-title":"Investigational drugs targeting FLT3 for leukemia","volume":"18","author":"Ustun","year":"2009","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2025.117849_bib55","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117849_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121177","article-title":"Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220)","volume":"10","author":"Zorn","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117849_bib57","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117849_bib58","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib59","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Gilteritinib: potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2025.117849_bib63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1570163817666200518075820","article-title":"FLT3 inhibition in acute myeloid leukaemia - current knowledge and future prospects","volume":"20","author":"Hogan","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2025.117849_bib64","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2014-10-605808","article-title":"Secondary mutations as mediators of resistance to targeted therapy in leukemia","volume":"125","author":"Daver","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2012.191","article-title":"Mutations of FLT3\/ITD confer resistance to multiple tyrosine kinase inhibitors","volume":"27","author":"Williams","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib66","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/cncr.28705","article-title":"Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations","volume":"120","author":"Alvarado","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.117849_bib67","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/leu.2015.165","article-title":"FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors","volume":"29","author":"Smith","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib68","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \"Gatekeeper\" F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117849_bib69","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2005-06-2469","article-title":"Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain","volume":"107","author":"Heidel","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib70","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1947601912466555","article-title":"The STAT5 inhibitor pimozide displays efficacy in models of acute myelogenous leukemia driven by FLT3 mutations","volume":"3","author":"Nelson","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ejmech.2025.117849_bib71","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1038\/onc.2016.41","article-title":"Aberrant activation of the PI3K\/mTOR pathway promotes resistance to sorafenib in AML","volume":"35","author":"Lindblad","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117849_bib72","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1182\/blood-2006-05-023804","article-title":"Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways","volume":"109","author":"Piloto","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","article-title":"SYK is a critical regulator of FLT3 in acute myeloid leukemia","volume":"25","author":"Puissant","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117849_bib74","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/leu.2015.147","article-title":"Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia","volume":"29","author":"Park","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074653","article-title":"Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication","volume":"8","author":"Natarajan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117849_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117849_bib77","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib78","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib79","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib80","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1535-7163.MCT-12-0129","article-title":"Breakdown of the FLT3-ITD\/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors","volume":"11","author":"Pietschmann","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117849_bib81","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1021\/jm800988r","article-title":"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases","volume":"52","author":"Mahboobi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib82","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/leu.2015.346","article-title":"The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3\/ITD acute myeloid leukemia cells","volume":"30","author":"Chang","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117849_bib83","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117849_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104367","article-title":"Targeting FLT3 for treating diseases: FLT3 inhibitors","volume":"30","author":"Rong","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.117849_bib85","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00277-023-05545-3","article-title":"Perspectives and challenges of small molecule inhibitor therapyfor FLT3-mutated acute myeloid leukemia","volume":"103","author":"Lap","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejmech.2025.117849_bib86","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/jm058033i","article-title":"Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase","volume":"49","author":"Mahboobi","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib87","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chembiol.2021.10.011","article-title":"Identification of a highly efficient dual type I\/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells","volume":"29","author":"Beyer","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117849_bib88","series-title":"Preparation of Substituted Arylamine Derivatives as Antitumor Agents","author":"Elbaum","year":"2003"},{"key":"10.1016\/j.ejmech.2025.117849_bib89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/molecules21010042","article-title":"The prodrug approach: a successful tool for improving drug solubility","volume":"21","author":"Jornada","year":"2015","journal-title":"Molecules (Basel)"},{"key":"10.1016\/j.ejmech.2025.117849_bib90","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1747-0285.2008.00734.x","article-title":"Novel aminomethylindole derivatives as inhibitors of pp60c-Src tyrosine kinase: synthesis and biological activity","volume":"72","author":"I\u015fg\u00f6r","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.117849_bib91","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jm2011436","volume":"55","author":"Xia","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib92","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1021\/jm0111200","article-title":"Synthesis and molecular modeling of new 1-aryl-3-4-arylpiperazin-1-yl-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors","volume":"45","author":"Or\u00fas","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib93","series-title":"Sepiapterin Reductase Inhibitors for the Treatment of Pain","author":"Blagg","year":"2011"},{"key":"10.1016\/j.ejmech.2025.117849_bib94","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1002\/anie.200901843","article-title":"Catalytic functionalization of indoles in a new dimension","volume":"48","author":"Bandini","year":"2009","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.117849_bib96","doi-asserted-by":"crossref","first-page":"9906","DOI":"10.1021\/acs.jmedchem.6b01280","article-title":"Chemical inhibition of human thymidylate kinase and structural insights into the phosphate binding loop and ligand-induced degradation","volume":"59","author":"Chen","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib97","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1016\/j.bmc.2016.06.010","article-title":"Synthesis and investigation of novel benzimidazole derivatives as antifungal agents","volume":"24","author":"Chandrika","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib98","series-title":"Pyrimidine FGFR4 Inhibitors","author":"Reynolds","year":"2016"},{"key":"10.1016\/j.ejmech.2025.117849_bib99","series-title":"Compounds that Inhibit MCL-1 Protein","author":"Harrington","year":"2018"},{"key":"10.1016\/j.ejmech.2025.117849_bib100","series-title":"Synthesis Method and Application of 2-amino-4-substituted Pyridine Derivative","author":"Zhang","year":"2013"},{"key":"10.1016\/j.ejmech.2025.117849_bib101","doi-asserted-by":"crossref","first-page":"11357","DOI":"10.1021\/jacs.7b07104","article-title":"Electrophilic zinc homoenolates: synthesis of cyclopropylamines from cyclopropanols and amines","volume":"139","author":"Mills","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117849_bib102","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1021\/jm401047q","article-title":"Synthesis and evaluation of multi-target-directed ligands against Alzheimer's disease based on the fusion of donepezil and ebselen","volume":"56","author":"Luo","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib103","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1002\/adsc.201900686","article-title":"Catalytic transfer hydrodebenzylation with low palladium loading","volume":"361","author":"Yakukhnov","year":"2019","journal-title":"Adv. Synth. Catal."},{"key":"10.1016\/j.ejmech.2025.117849_bib104","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cmdc.201402098","article-title":"Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds","volume":"9","author":"Sundriyal","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117849_bib105","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1021\/jm901699j","article-title":"Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor","volume":"53","author":"Fujimoto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib106","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1021\/acs.jmedchem.7b00724","article-title":"Amidoalkylindoles as potent and selective cannabinoid type 2 receptor agonists with in vivo efficacy in a mouse model of multiple sclerosis","volume":"60","author":"Shi","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib107","unstructured":"Erik Verner; \u2020; Bradley A. Katz; \u2021; Jeffrey R. Spencer; Darin Allen; Jason Hataye; Witold Hruzewicz; Hon C. Hui; Aleksandr Kolesnikov; Yong Li; Christine Luong; Arnold Martelli; Kesavan Radika; \u00a7; Roopa Rai; Miles She; William Shrader; Paul A. Sprengeler; Sean Trapp; Jing Wang; Wendy B. Young; \u2020 and; and Richard L. Mackman\u2217. Development of Serine Protease Inhibitors Displaying a Multicentered Short (<2.3 \u00c5) Hydrogen Bond Binding Mode: Inhibitors of Urokinase-type Plasminogen Activator and Factor Xa."},{"key":"10.1016\/j.ejmech.2025.117849_bib108","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117849_bib109","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugated in combination with kinase inhibitors for treatment af AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117849_bib117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.exphem.2012.10.016","article-title":"Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases","volume":"41","author":"Polzer","year":"2013","journal-title":"Exp. Hematol."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117849_bib110","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-07-1873","article-title":"Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591","volume":"14","author":"Vempati","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117849_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in Acute Myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117849_bib112","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acschembio.8b01020","article-title":"Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors","volume":"14","author":"Reinecke","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117849_bib113","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1242\/dev.046995","article-title":"Axonal projections of mechanoreceptive dorsal root ganglion neurons depend on Ret","volume":"137","author":"Honma","year":"2010","journal-title":"Development"},{"key":"10.1016\/j.ejmech.2025.117849_bib114","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117849_bib115","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.18632\/oncotarget.27222","article-title":"Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells","volume":"10","author":"Kawase","year":"2019","journal-title":"Oncotarget"},{"issue":"Endocrinol. Metab. 40","key":"10.1016\/j.ejmech.2025.117849_bib121","first-page":"E779","article-title":"Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes","volume":"277","author":"Cornish","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"38","key":"10.1016\/j.ejmech.2025.117849_bib123","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","article-title":"Comparison of the kinase profile of Midostaurin (Rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to leukemia therapy","volume":"57","author":"Manley","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117849_bib124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OTT.S236740","article-title":"FMS-Like tyrosine kinase 3 inhibitors in the treatment of Acute Myeloid leukemia: an update on the emerging evidence and safety profile","volume":"16","author":"Garciaz","year":"2023","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2025.117849_bib125","doi-asserted-by":"crossref","unstructured":"Elli D. Novatcheva, Yasmine Anouty, Ila Saunders, James K. Mangan, Aaron M. Goodman, FMS-Like tyrosine kinase 3 inhibitors for the treatment of Acute Myeloid leukemia. Clin. Lymphoma Myeloma Leuk., 22 (3), e161\u2013e184, PMID: 34649791.","DOI":"10.1016\/j.clml.2021.09.002"},{"key":"10.1016\/j.ejmech.2025.117849_bib126","article-title":"Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection","volume":"9","author":"Bruno Morelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejmech.2025.117849_bib127","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF01192309","article-title":"Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity","volume":"118","author":"Bernhardt","year":"1992","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117849_bib116","doi-asserted-by":"crossref","first-page":"31461","DOI":"10.1074\/jbc.C300186200","article-title":"Structure of a c-kit product complex reveals the basis for kinase transactivation","volume":"278","author":"Mol","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib119","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/ja00124a002","article-title":"A second generation force field for the simulation of proteins, nucleic acids, and organic molecules","volume":"117","author":"Cornell","year":"1995","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117849_bib120","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jcc.540100804","article-title":"Validation of the general purpose tripos 5.2 force field","volume":"10","author":"Clark","year":"1989","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.117849_bib95","series-title":"Functionalized Heterocycles as Chemokine Receptor Modulators","author":"Harriman","year":"2000"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T08:41:09Z","timestamp":1754988069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":122,"alternative-id":["S0223523425006142"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117849","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel water-soluble and highly efficient dual type I\/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117849"}}